Jiang Jialin, Zhu Xinlei, Li Shukun, Yan Qun, Ma Jian
Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Cancer Research Institute, School of Basic Medicine Sciences, Xiangya School of Medicine, Central South University, Changsha, China.
J Med Virol. 2025 Feb;97(2):e70192. doi: 10.1002/jmv.70192.
Epstein-Barr virus (EBV) infection is closely associated with the development of various tumors such as lymphomas and epithelial cancers. EBV has a discrete life cycle with latency and lytic phases. In recent years, significant progress has been made in the understanding of the mechanism underlying the transition of EBV from latency to lytic replication. Multiple new lytic activation factors have been emerged and promoted our understanding of this field. In addition, we have comprehensively presented the existing therapeutic strategies and their relationship to the mechanism underlying the transition of EBV from latency to lytic replication in this review, such as lytic induction therapy and drugs to prevent EBV from entering the lytic phase fully utilize the EBV reactivation mechanisms. This year marks the 60th anniversary of the discovery of EBV, and building a bridge between the mechanism of EBV reactivation and the treatment may help us to design new approaches for treating EBV-associated diseases.
爱泼斯坦-巴尔病毒（EBV）感染与淋巴瘤和上皮癌等多种肿瘤的发生密切相关。EBV具有潜伏期和裂解期的离散生命周期。近年来，在理解EBV从潜伏期向裂解复制转变的潜在机制方面取得了重大进展。多个新的裂解激活因子已出现，促进了我们对该领域的理解。此外，在本综述中，我们全面介绍了现有的治疗策略及其与EBV从潜伏期向裂解复制转变的潜在机制的关系，如裂解诱导疗法和防止EBV进入裂解期的药物，充分利用了EBV再激活机制。今年是EBV发现60周年，在EBV再激活机制与治疗之间架起桥梁可能有助于我们设计治疗EBV相关疾病的新方法。
